The DOI matches its Crossref record.
Nitazoxanide versus Vancomycin in Clostridium difficile Infection: A Randomized, Double‐Blind Study
Abstract
BACKGROUND: Vancomycin is the only US Food and Drug Administration-approved drug for treatment of Clostridium difficile infection (CDI). Metronidazole has been widely used for this purpose but may be inferior to vancomycin, especially for hospitalized patients with severe disease. We report a prospective, double-blind, randomized controlled trial comparing nitazoxanide with vancomycin for treatment of CDI. METHODS: Fifty patients with CDI were randomized to receive vancomycin or nitazoxanide for 10 days. An initial response was considered to be the absence of all CDI symptoms between days 11 and 13, and a final response was considered to be lack of symptom recurrence by day 31. RESULTS: One patient fulfilled an exclusion criterion and was removed from the study. Twenty-seven patients received vancomycin, and 23 received nitazoxanide; 23 and 18 patients, respectively, completed the full course of treatment. Initial responses occurred in 20 (74%) of 27 patients treated with vancomycin and in 17 (77%) of 22 patients treated with nitazoxanide (95% confidence interval, -24% to +28%). In those who completed therapy, response rates were 87% (20 of 23 patients) in the vancomycin group and 94% (17 of 18 patients) in the nitazoxanide group (95% confidence interval, -18% to +30%). Times to complete resolution of symptoms were similar in the 2 groups (P = .55). Two patients in the vancomycin group and 1 patient in the nitazoxanide group experienced relapse within 31 days after beginning treatment. Sustained response rates were 78% (18 of 23 patients) for the vancomycin group, and 89% (16 of 18 patients) for the nitazoxanide group (95% confidence interval, -18% to +35%). CONCLUSIONS: The small sample precludes conclusions about noninferiority of nitazoxanide to vancomycin. Nevertheless, this is the first recent randomized controlled trial to compare any antimicrobial agent other than metronidazole with vancomycin. Results suggest that nitazoxanide may be as effective as vancomycin in treating CDI. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00384527.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,215
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Rossignol, J.-F. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.07.014 · Cited by 556
Self-citationBauer, M. P., Kuijper, E. J., & van Dissel, J. T. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03099.x · Cited by 366
Antibiotic treatment for Clostridium difficile -associated diarrhoea in adults
Nelson, R. L., Suda, K. J., & Evans, C. T. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004610.pub5 · Cited by 366
Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options
Lo Vecchio, A., & Zacur, G. M. (2012) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32834bc9a9 · Cited by 183
Metadata
- Authors
- Musher, D. M., Logan, N., Bressler, A. M., Johnson, D. P., & Rossignol, J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-02-15
- Volume
- 48
- Issue
- 4
- Pages
- e41-e46
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2110883478
- Cited by
- 186
- References
- 0
- FWCI
- 13.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nitazoxanide versus Vancomycin in Clostridium difficile Infection: A Randomized, Double‐Blind Study. https://app.cochat.ai/papers/10.1086/596552
- The paper
- Musher, D. M., Logan, N., Bressler, A. M., Johnson, D. P., & Rossignol, J. (2009). Nitazoxanide versus Vancomycin in Clostridium difficile Infection: A Randomized, Double‐Blind Study. Clinical Infectious Diseases. https://doi.org/10.1086/596552
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.